Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression.

Böttcher R, Henderson DJ, Dulla K, van Strijp D, Waanders LF, Tevz G, Lehman ML, Merkle D, van Leenders GJ, Baillie GS, Jenster G, Houslay MD, Hoffmann R.

Br J Cancer. 2015 Nov 17;113(10):1502-11. doi: 10.1038/bjc.2015.335.

2.

The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells.

Henderson DJ, Byrne A, Dulla K, Jenster G, Hoffmann R, Baillie GS, Houslay MD.

Br J Cancer. 2014 Mar 4;110(5):1278-87. doi: 10.1038/bjc.2014.22. Epub 2014 Feb 11.

3.

The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status.

van Strijp D, de Witz C, Heitkötter B, Huss S, Bögemann M, Baillie GS, Houslay MD, Bangma C, Semjonow A, Hoffmann R.

Prostate Cancer. 2019 Jun 2;2019:8107807. doi: 10.1155/2019/8107807. eCollection 2019.

4.

Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.

Alves de Inda M, van Strijp D, den Biezen-Timmermans E, van Brussel A, Wrobel J, van Zon H, Vos P, Baillie GS, Tennstedt P, Schlomm T, Houslay MD, Bangma C, Hoffmann R.

Eur Urol Focus. 2018 Apr;4(3):376-384. doi: 10.1016/j.euf.2017.05.010. Epub 2017 Jun 13.

5.
6.

Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.

Böttcher R, Dulla K, van Strijp D, Dits N, Verhoef EI, Baillie GS, van Leenders GJ, Houslay MD, Jenster G, Hoffmann R.

Oncotarget. 2016 Oct 25;7(43):70669-70684. doi: 10.18632/oncotarget.12204.

7.

High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.

Smit FP, Salagierski M, Jannink S, Schalken JA.

BJU Int. 2013 May;111(5):836-42. doi: 10.1111/bju.12119.

8.

ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.

Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T, Kameda Y, Sakuma Y, Nakamura Y, Harada M, Tsuchiya E.

Mod Pathol. 2010 Nov;23(11):1492-8. doi: 10.1038/modpathol.2010.149. Epub 2010 Aug 6.

9.

Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.

Rubio-Briones J, Fernández-Serra A, Calatrava A, García-Casado Z, Rubio L, Bonillo MA, Iborra I, Solsona E, López-Guerrero JA.

J Urol. 2010 May;183(5):2054-61. doi: 10.1016/j.juro.2009.12.096. Epub 2010 Mar 19.

PMID:
20303538
10.

Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.

Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC, Trapman J.

Clin Cancer Res. 2009 Oct 15;15(20):6398-403. doi: 10.1158/1078-0432.CCR-09-1176. Epub 2009 Oct 13.

11.

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.

Brase JC, Johannes M, Mannsperger H, Fälth M, Metzger J, Kacprzyk LA, Andrasiuk T, Gade S, Meister M, Sirma H, Sauter G, Simon R, Schlomm T, Beissbarth T, Korf U, Kuner R, Sültmann H.

BMC Cancer. 2011 Dec 5;11:507. doi: 10.1186/1471-2407-11-507.

12.

Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.

Cai C, Wang H, Xu Y, Chen S, Balk SP.

Cancer Res. 2009 Aug 1;69(15):6027-32. doi: 10.1158/0008-5472.CAN-09-0395. Epub 2009 Jul 7.

13.
14.

Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.

Kolar Z, Burdova A, Jamaspishvili T, Bouchal J, Kucerova R, Bienova M, Kral M, Student V.

Neoplasma. 2014;61(1):9-16.

PMID:
24195515
15.

TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.

Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI.

Eur Urol. 2011 Nov;60(5):897-904. doi: 10.1016/j.eururo.2011.07.011. Epub 2011 Jul 14.

16.

Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.

He J, Sun X, Shi T, Schepmoes AA, Fillmore TL, Petyuk VA, Xie F, Zhao R, Gritsenko MA, Yang F, Kitabayashi N, Chae SS, Rubin MA, Siddiqui J, Wei JT, Chinnaiyan AM, Qian WJ, Smith RD, Kagan J, Srivastava S, Rodland KD, Liu T, Camp DG 2nd.

Mol Oncol. 2014 Oct;8(7):1169-80. doi: 10.1016/j.molonc.2014.02.004. Epub 2014 Feb 21.

17.

Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.

Roudier MP, Winters BR, Coleman I, Lam HM, Zhang X, Coleman R, Chéry L, True LD, Higano CS, Montgomery B, Lange PH, Snyder LA, Srivastava S, Corey E, Vessella RL, Nelson PS, Üren A, Morrissey C.

Prostate. 2016 Jun;76(9):810-22. doi: 10.1002/pros.23171. Epub 2016 Mar 16.

18.

A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.

Qu X, Randhawa G, Friedman C, O'Hara-Larrivee S, Kroeger K, Dumpit R, True L, Vakar-Lopez F, Porter C, Vessella R, Nelson P, Fang M.

Cancer Genet. 2013 Jan-Feb;206(1-2):1-11. doi: 10.1016/j.cancergen.2012.12.004. Epub 2013 Jan 24.

19.

TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.

Swanson TA, Krueger SA, Galoforo S, Thibodeau BJ, Martinez AA, Wilson GD, Marples B.

Prostate. 2011 Oct 1;71(14):1548-58. doi: 10.1002/pros.21371. Epub 2011 Mar 10.

PMID:
21394739
20.

Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays.

Jhavar S, Reid A, Clark J, Kote-Jarai Z, Christmas T, Thompson A, Woodhouse C, Ogden C, Fisher C, Corbishley C, De-Bono J, Eeles R, Brewer D, Cooper C.

J Mol Diagn. 2008 Jan;10(1):50-7. doi: 10.2353/jmoldx.2008.070085. Epub 2007 Dec 28.

Supplemental Content

Support Center